Trastuzumab-induced cardiotoxicity is a frequent but generally mild adverse event, highlighting the need for further studies to define risk and protective factors.
TIC is a frequent, albeit generally mild, adverse event in clinical practice. Further studies are warranted to better define the risk of and protective factors for TIC.
Farolfi et al. (2013) studied this question.